Ace investor Rakesh Jhunjhunwala removes money from this stock - What should you do? Find out
Earlier, Jhunjhunwala held about 2.41% stake in Fortis. So far, in six month’s period, Fortis has only grown by 1.96% which means there were barely any earnings made by Jhunjhunwala in this stock.
Rakesh Jhunjhunwala wealth drops by 16%, but this did not stop his buying spree! These 6 stocks found more love from Dalal Street king
Guru Purnima 2019: Top money lessons - Warren Buffet to Rakesh Jhunjhunwala, 'guru gyan' to profit from
Rakesh Jhunjhunwala’s money making stock turns not-so-favorite on Dalal Street today- This Big Bull favourite drops over 14% 
This Rakesh Jhunjhunwala linked stock is a multibagger going forward - Here’s why you should buy 
This stock has become a multibagger for Big Bull Rakesh Jhunjhunwala - Find out why you should buy! Massive changes have taken place in the ace investor Rakesh Jhunjhunwala’s portfolio, as he continues to remove money one-by-one from his 'once favorite' stocks. Interestingly, Jhunjhunwala has reduced his holding in his latest investment during December 2018 (Q3FY19) quarter, which is very surprising and does raise many eyebrows to whether one should also stay invested in the stock. Fortis Healthcare has lost some love of Jhunjhunwala. Fortis along with SpiceJet were two newly added stocks in Jhunjhunwala’s portfolio during September 2018 quarter. While SpiceJet is yet to announce its shareholding pattern, but Fortis public holding reveals the big bull’s exit.
Fortis Healthcare, in fact, has seen the biggest cut by Jhunjhunwala so far as compared to other stocks which also saw similar sentiments from the bull investor. Jhunjhunwala has cut his holding by 0.75% in Fortis. With this, now he holds about 1.66% stake in Fortis with 12,500,000 equity shares worth Rs 169.4 crore.
Earlier, Jhunjhunwala held about 2.41% stake in Fortis. So far, in six month’s period, Fortis has only grown by 1.96% which means there were barely any earnings made by Jhunjhunwala in this stock.
#ResultsOnZB | कैसे रहेंगे मारुति और L&T के नतीजे? समझिए Q3 नतीजों का अनुमान कुशल गुप्ता से।@KushalGupta44 @AnilSinghviZEE @deepaliranaa pic.twitter.com/7zVKprHBKl
— Zee Business (@ZeeBusiness) January 25, 2019
Should you invest in Fortis?
Analysts at Edelweiss Securities have given a Buy Call on Fortis with a price target of Rs 141 ahead. On the company’s Q3FY19, they added, “We expect the top line to grow 5% YoY after recording four continuous quarters of decline—hospital business to grow at 4% YoY and SRL at 8%. This will be accompanied by EBITDAC growth of 8% YoY on a weak base and return to 70% occupancy.”
Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and 314 diagnostic centres.
